**Name of Journal:** *World Journal of Hepatology*

**Manuscript NO:** 76109

**Manuscript Type:** ORIGINAL ARTICLE

***Clinical and Translational Research***

**Transcriptome changes in stages of non-alcoholic fatty liver disease**

Aljabban J *et al*. Transcriptome changes in stages

Jihad Aljabban, Michael Rohr, Saad Syed, Kamal Khorfan, Vincent Borkowski, Hisham Aljabban, Michael Segal, Mohamed Mukhtar, Mohammed Mohammed, Maryam Panahiazar, Dexter Hadley, Ryan Spengler, Erin Spengler

**Jihad Aljabban, Vincent Borkowski, Michael Segal, Ryan Spengler,** Department of Medicine, University of Wisconsin Hospital and Clinics, Madison, WI 53792, United States

**Michael Rohr,** Department of Medicine, University of Central Florida College of Medicine, Orlando, FL 32827, United States

**Saad Syed,** Department of Medicine, Northwestern Memorial Hospital, Chicago, IL 60611, United States

**Kamal Khorfan,** Department of Gastroenterology and Hepatology, University of California San Francisco-Fresno , Fresno, CA 93701, United States

**Hisham Aljabban,** Department of Medicine, Barry University, Miami, FL 33161, United States

**Mohamed Mukhtar,** Department of Medicine, Michigan State University College of Human Medicine, East Lansing, MI 49503, United States

**Mohammed Mohammed,** Department of Medicine, Windsor University School of Medicine, Saint Kitts 1621, Cayon, Saint Kitts and Nevis

**Maryam Panahiazar,** Department of Surgery, University of California San Francisco, San Francisco, CA 94305, United States

**Dexter Hadley,** Department of Artificial Intelligence, Pathology, University of Central Florida College of Medicine , Orlando, FL 32827, United States

**Erin Spengler,** Department of Gastroenterology and Hepatology, University of Wisconsin Hospital and Clinics, Madison, WI 53792, United States

**Author contributions:** All authors contributed to conception or designing of the work, data collection, drafting manuscript, critical revision of manuscript, final edits and approval the manuscript.

**Corresponding author: Jihad Aljabban, MD, MSc, Academic Research, Doctor,** Department of Medicine, University of Wisconsin Hospital and Clinics, 600 Highland Avenue, Madison, WI 53792, United States. jaljabban@uwhealth.org

**Received:** March 2, 2022

**Revised:** April 29, 2022

**Accepted:** June 14, 2022

**Published online:** July 27, 2022

**Abstract**

BACKGROUND

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the United States and globally. The currently understood model of pathogenesis consists of a ‘multiple hit’ hypothesis in which environmental and genetic factors contribute to hepatic inflammation and injury.

AIM

To examine the genetic expression of NAFLD and non-alcoholic steatohepatitis (NASH) tissue samples to identify common pathways that contribute to NAFLD and NASH pathogenesis.

METHODS

We employed the Search Tag Analyze Resource for Gene Expression Omnibus platform to search the The National Center for Biotechnology Information Gene Expression Omnibus to elucidate NAFLD and NASH pathology. For NAFLD, we conducted meta-analysis of data from 58 NAFLD liver biopsies and 60 healthy liver biopsies; for NASH, we analyzed 187 NASH liver biopsies and 154 healthy liver biopsies.

RESULTS

Our results from the NAFLD analysis reinforce the role of altered metabolism, inflammation, and cell survival in pathogenesis and support recently described contributors to disease activity, such as altered androgen and long non-coding RNA (lncrna) activity. The top upstream regulator was found to be sterol regulatory element binding transcription factor 1 (SREBF1), a transcription factor involved in lipid homeostasis. Downstream of SREBF1, we observed upregulation in CXCL10, HMGCR, HMGCS1, fatty acid binding protein 5 (FABP5), paternally expressed imprinted gene 10 (PEG10), and downregulation of sex hormone-binding globulin (SHBG) and insulin-like growth factor 1 (IGF1). These molecular changes reflect low-grade inflammation secondary to accumulation of fatty acids in the liver. Our results from the NASH analysis emphasized the role of cholesterol in pathogenesis. Top canonical pathways, disease networks, and disease functions were related to cholesterol synthesis, lipid metabolism, adipogenesis, and metabolic disease. Top upstream regulators included pro-inflammatory cytokines tumor necrosis factor (TNF) and IL1B, PDGF BB, and beta-estradiol. Inhibition of beta-estradiol was shown to be related to derangement of several cellular downstream processes including metabolism, extracellular matrix deposition, and tumor suppression. Lastly, we found riciribine (an AKT inhibitor) and ZSTK-474 (a PI3K inhibitor) as potential drugs that targeted the differential gene expression in our dataset.

CONCLUSION

In this study we describe several molecular processes that may correlate with NAFLD disease and progression. We also identified ricirbine and ZSTK-474 as potential therapy.

**Key Words:** Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Bioinformatics; AKT inhibitor; Therapy

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation：** Aljabban J, Rohr M, Syed S, Khorfan K, Borkowski V, Aljabban H, Segal M, Mukhtar M, Mohammed M, Panahiazar M, Hadley D, Spengler R, Spengler E. Transcriptome changes in stages of non-alcoholic fatty liver disease. *World J Hepatol* 2022; 14(7): 1382-1397

**URL**: <https://www.wjgnet.com/1948-5182/full/v14/i7/1382.htm>

**DOI**: https://dx.doi.org/10.4254/wjh.v14.i7. 1382

**Core Tip:** Our results from the non-alcoholic fatty liver disease analysis reinforce the role of altered metabolism, inflammation, and cell survival in pathogenesis and support recently described contributors to disease activity, such as altered androgen and lncrna activity. The top upstream regulator was found to be sterol regulatory element binding transcription factor 1 (SREBF1), a transcription factor involved in lipid homeostasis. Downstream of SREBF1, we observed upregulation in CXCL10, HMGCR, HMGCS1, FABP5, PEG10, and downregulation of SHBG and IGF1. These molecular changes reflect low-grade inflammation secondary to accumulation of fatty acids in the liver. Our results from the NASH analysis emphasized the role of cholesterol in pathogenesis. Top upstream regulators included pro-inflammatory cytokines TNF and IL1B, PDGF BB, and beta-estradiol. Inhibition of beta-estradiol was shown to be related to derangement of several cellular downstream processes including metabolism, extracellular matrix deposition, and tumor suppression. Lastly, we found riciribine (an AKT inhibitor) and ZSTK-474 (a PI3K inhibitor) as potential drugs that targeted the differential gene expression in our dataset.

**INTRODUCTION**

Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease that is characterized by the accumulation of triglycerides within hepatocytes. This process strongly resembles alcohol-induced fatty liver damage but occurs in the absence of excessive alcohol consumption. Akin to obesity, rates of NAFLD are burgeoning and represent a growing health burden; it is estimated that the global disease prevalence is between 20-30%[1]. There is growing evidence that NAFLD is a multisystem disease with both intra- and extra-hepatic manifestations, with strong association between NAFLD and type 2 diabetes mellitus and metabolic syndrome[2].

NAFLD comprises of a spectrum of disease that includes simple steatosis, non-alcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma (HCC). While hepatic steatosis is seen as a generally benign state, NASH is considered a progressive disease state with increased risk of intra- and extra-hepatic disease complications, including cirrhosis[3]. The gold-standard to diagnose NASH is an invasive liver biopsy. As there are no effective non-invasive diagnostic techniques, which makes estimating the true prevalence of NASH difficult; however, it has been estimated that up 25% of patients with NAFLD have concurrent NASH[4]. As rates of NAFLD continue to increase, it is estimated that NAFLD-related cirrhosis will soon surpass chronic hepatitis as the leading indication for liver transplantation[5].

The increasing prevalence and health burden of NAFLD has made it imperative to understand the pathogenesis of this disease process. The most current, best understood model of NAFLD conceptualizes a ‘multiple hit’ hypothesis in which interactions between genetics and environmental factors promote inflammation, cellular injury, and liver damage[6]. These ‘hits’ include lipid accumulation secondary to diet and lifestyle, obesity, and insulin resistance, all of which predispose the liver to inflammation and fibrosis. However, the mechanisms by which these hits promote disease progression are still poorly understood. In this meta-analysis, we aim to use bioinformatics of publicly available data to elucidate the most common genetic pathways involved in NAFLD and identify potential therapeutic targets for intervention.

**MATERIALS AND METHODS**

The National Center for Biotechnology Information Gene Expression Omnibus (GEO) is one of the largest databases available to researchers. The Search, Tag, Analyze, Resource GEO, or STARGEO, was developed to tag samples from the GEO database and produce robust meta-analyses. The GEO database is a genomics repository comprised of all published samples from omics studies. Briefly, STARGEO uses a standard random model for meta-analysis to generate both meta *P* values and effects size across studies[7]. Study weight percentages were calculated using the inverse variance method *via* the DerSimonian-Laird estimate[8]. The STARGEO “Tagging” interface was used to gather samples under the “NAFLD,” “NASH,” and “NASH\_NAFLD\_Control” tag to conduct two separate meta-analyses: one comparing liver biopsies from NAFLD patients to healthy liver controls and the other comparing liver biopsies from NASH to healthy controls.

Series GSE48452, GSE63067, GSE66676, and GSE107231 were used to gather NAFLD, NASH, and healthy liver samples[9-12]. Studies were found by searching NAFLD or NASH under human samples on stargeo.org. Studies selected for analysis had to meet the following criteria: expression analysis was conducted on liver biopsies, the study included contained patients meeting NAFLD or NASH criteria and had matched healthy controls, and biopsies met definitive diagnosis of liver steatosis as below.

In these studies, liver biopsies were performed to diagnose liver disease and healthy liver biopsies were defined as having less than < 5% steatosis and patients with evidence of viral hepatitis, alcoholic consumption, and hemochromatosis were excluded. Standard histopathological analysis by blinded pathologists were used to defined NASH, NAFLD, and healthy liver samples[13]. For example, GSE48452 investigated intra-individual biopsies taken pre and post-bariatric surgery meeting NAFLD, NASH, and healthy liver criteria as above. Only pre-bariatric samples were tagged. For the NAFLD analysis, there was a total of 58 NAFLD liver biopsies and 60 healthy liver biopsies. The NASH analysis featured 187 NASH liver biopsies and 154 healthy liver biopsies.

We were able to extract approximately 20000 genes for each of the meta-analyses conducted using STARGEO. We analyzed gene signature outputs with Ingenuity Pathway Analysis (IPA) to genes showing statistical significance (*P <* 0.05) and an absolute experimental log ratio greater than 0.1 between case and control samples[14]. The genes included in our analysis are further detailed in Tables 1 and 2. IPA allowed us to define top canonical pathways, disease functions, disease networks, and potential upstream regulators that define NAFLD and NASH pathogenesis. Regulator analysis identifies upstream regulators that best explain the genetic expression in our dataset with *P* values reflecting the degree of overlap of known effector targets and the gene signature analyzed in IPA. We also used the global molecular network feature of IPA to identify top disease networks. IPA ranks networks from the Global Molecular Network based on the number of focus genes from given networks that match with our analysis. Significance is represented by the p-score, as previously described[14].

To find potential drug interactions, we used clue.io to analyze our dataset[15]. We inversed the gene expression pattern from the meta-analysis and used the “list-maker” function to identify drugs (Table 3). We focused on HEPG2 cell lines given they are immortalized HCC cells that relate most closely to the cells studied in our analysis.

All data analyzed were taken from Gene Expression Omnibus. There was no interaction or intervention with human subjects and no involvement with access to identifiable private patient information. As such, no Institutional Review Board approval was necessary.

**RESULTS**

***Top canonical pathways and genes of interest from NAFLD and NASH analysis***

From STARGEO, we were able to extract approximately 20000 genes from our analysis of NAFLD and NASH liver biopsies compared to normal biopsy controls. Table 1 summarizes top upregulated and downregulated genes from the two analyses. Only genes that demonstrated statistically significant (*P <* 0.05) differences in up-and down-regulation and absolute experimental log ratios of 0.1 were analyzed in IPA. Additionally, we used IPA to classify the top canonical pathways for NAFLD and NASH. P values and experimental log ratios are included in Tables 1 and 2.

For the NAFLD analysis, the genetic changes and top canonical pathways illustrate several disease processes such as dysregulated metabolism, immune cell recruitment, and altered signal transduction. IPA identified liver X receptor / retinoid X receptor activation (*P* = 4.35E-05), superpathway of cholesterol biosynthesis (*P* = 1.08E-04), granulocyte adhesion and diapedesis (2.34E-04), cAMP response element binding protein (CREB) signaling (*P* = 6.35E-04), and mevalonate pathway (*P* = 8.96E-04) as top canonical pathways. Among the most upregulated genes are the long non-coding RNAs (lncrna), X-inactive specific transcript (XIST), and LINC00885, with the role of lncrna in liver disease playing an increasing role[16,17]. Additionally, we found upregulation of tumorigenic proteins such as PEG10 and phosphodiesterase 11A[18,19]. We also noted dysregulated metabolism and increased lipogenesis through upregulation of inositol hexakisphosphate kinase (IP6K3), flavin containing monooxygenase 1, perilipin 1, 3-hydroxy-3-methylglutaryl coenzyme A synthase, HMG-CoA reductase, FABP5, and downregulation of insulin-like growth factor binding protein 2, and IGF1[20-22]. Upregulation of steroid 5-alpha reductase 2 and downregulation of SHBG and nuclear receptor subfamily 0 group B member 2 leads to higher androgen activity with implication in liver disease[23]. Interestingly, we found downregulation of the circadian rhythm gene period circadian regulator 3 (PER3)[24]. There was also upregulation of several chemoattractants, including CXCL10. Lastly, we noted downregulation of the glycoprotein chitinase 3 Like 1, which regulates several cellular processes including proliferation, differentiation, inflammation, and others[25].

Similarly, the gene expression changes and top canonical pathways from the NASH analysis detailed several pathologic processes. IPA identified cholesterol biosynthesis and insulin-like growth factor 1 (IGF-1) signaling as top canonical pathways. We found upregulation of genes involved in bile acid synthesis and carnitine synthesis including cholesterol 7 alpha hydroxylase (CYP7A1) and gamma-butyrobetaine hydroxylase 1 (BBOX1), respectively[26-28]. Notably, we saw upregulation of the novel myokine fibronectin type 3 (FNDC5), which correlated with NAFLD severity and extracellular matrix deposition[29]. Interestingly, we found upregulation of the lamin-associated gene muscular LMNA interacting protein. Lamins and lamin-associated proteins have implications in liver disease[30].We also found upregulation of several pro-inflammatory genes including the interleukin 13 receptor and the immunoglobin receptor Fc alpha and mu receptor[31]. Our genetic analysis also highlighted dysregulated apoptosis through the downregulation of pro-apoptotic regulators such as the matricellular protein cysteine-rish angiogenic inducer 61 (CYR61), FOS protein (modulates JUN signaling), and Ras related dexamethasone induced 1 (RASD1) from the RAS family[32-24]. Lastly, we found downregulation of insulin-like growth factor binding protein-2 (IGFBP2), similar for our NAFLD analysis above, and the nicotinamide phosphoribosyltransferase, a rate-limiting enzyme in the NAD+ pathway[35].

***Top disease function and networks***

NAFLD and NASH are the result of several complex disease processes in tandem. To define these processes, we used IPA to identify top disease function and networks of interest. In the NAFLD analysis, disease processes were largely related to lipid regulation, inflammation, and hepatic fibrosis and injury (Table 2). Similarly, the disease functions in NASH included processes related to lipid metabolism in addition to other functions such as cancer and cell death and survival. Figure 1 illustrates one of the disease functions, adipogenesis, in the NASH analysis.

Next, we employed the IPA Disease Network feature to further elucidate the pathologic changes in NAFLD and NASH. IPA takes genes from the analyzed dataset and superimposes it onto curated information from the Ingenuity Knowledge base[14]. In Table 3, we detail the top disease networks identified for NAFLD and NASH. Figure 2 details the lipid metabolism network from the NAFLD analysis.

*Top upstream regulators and causal analysis*

To propose potential drivers of NAFLD and NASH pathogenesis and their downstream effector genes, we used IPA Upstream Regulator analysis[14]. In the NAFLD analysis, beta-estradiol (*P* = 9.42E-12), cholesterol (*P* = 1.79E-11), TNF (*P* = 8.73E-10), nuclear receptor coactivator (*P* = 1.22E-09), and sterol regulatory element binding transcription factor 1 (SREBF1) (*P* = 12.8E-08) were top upstream regulators. Of these regulators, SREBF1 demonstrated the highest z-score (2.200), demonstrating how the gene expression signature reflects known downstream SREBF1 gene signaling. Next, we investigated how the genes described above are affected by SREBF family (Figure 3). We see activation of SREBF1 and SREBF2 is linked to the changes in expression noted in CXCL10, FABP5, IGF1, HMGCR, HMGCS1, sex hormone binding globulin, and PEG10.

In the NASH analysis, TNF (*P* = 1.22E-19), lipopolysaccharide or LPS (*P* = 6.27E-16), beta estradiol (*P* = 1.42E-15, with predicted inhibition), interleukin 1B or IL1B (*P* = 1.78E-14), and platelet-derived growth factor BB or PDGF BB (*P* = 1.90E-14) were top upstream regulators. Beta-estradiol demonstrates anti-fibrotic effects in the liver, so we investigated its downstream effects in our dataset (Figure 4). Inhibition of beta-estradiol activity is reflected by the changes we noted in the top upregulated genes including crystallin alpha A, BBOX1, CYP7A1, and FNDC5 and top downregulated genes including IGFBP2, nicotinamidenphosphoribosyltransferase pseudogene 1 (NAMP1), and RASD1 genes in our dataset described above. In addition, IPA related inhibition of beta-estradiol to other gene expression changes of interest including upregulation of the PEG10, squalene epoxidase (SQLE), IP6K3 and downregulation of the tumor suppressor Kruppel-like factor 6 (KLF6)[36,37].

***Therapeutic analysis***

To investigate potential drug targets from our dataset, we utilized clue.io. We inputted genes that were both upregulated and downregulated in our NAFD and NASH dataset (see Figure 5). We used the query tool from the platform and focused on HEPG2 cell lines, immortalized HCC cells. By looking at compounds that inverse the pathologic expression patterns in our meta-analyses, we identified riciribine (an AKT inhibitor) and ZSTK-474 (a PI3K inhibitor) as potential therapeutic compounds that target the genes in our investigation (see Table 3).

**DISCUSSION**

NAFLD represents a growing health burden, with an astonishing prevalence of 25% of the global population[38]. A better understanding of pathogenesis is needed to tackle this herculean disease. Here, we use meta-analysis of public data using our STARGEO platform in search of insights to disease and potential therapeutic targets. The gene expression profiles from our analyses can elucidate function and regulatory patterns to disease[39]. Our results from the NAFLD analysis reinforce the role of altered metabolism, inflammation, and cell survival and supports recently described contributors to disease such as altered androgen and lncrna activity[17,23,40].

Our results demonstrated several changes that are implicated in altered lipid and metabolic homeostasis. It is the accumulation of lipids that lead to several downstream effects that characterized NAFLD development and progression[20,41]. For example, lipid droplets in hepatocytes can lead to hepatic insulin resistance, decreased autophagy, oxidative stress, and interaction with several transcription factors such as SREBF[20]. These lipid droplets can form through the activity of proteins from the perilipin family, such as perilipin 1 (PLN1), which was upregulated in our dataset (Table 2)[20]. “Superpathway of Cholesterol Biosynthesis” was one of the top canonical pathways, and several top disease functions and networks were related to lipid accumulation (Tables 1-3). In addition, cholesterol and SREBF1, a transcription factor involved in lipid homeostasis, were top upstream regulators[42]. SREBF1 stimulates accumulation of lipids in hepatocytes through activation of patatin-like phospholipase domain-containing 3 (PNPAL3)[43]. In our results, we illustrate how downstream signaling of SREBF1 and SREBF2 Leads to fatty acid accumulation and other disease functions. Downstream of SREBF1 and SREBF2 signaling, we noted upregulation of CXCL10, HMGCR, HMGCS1, FABP5, and PEG10 in addition to downregulation of SHBG and IGF1. HMGCR catalyzes the first reaction of cholesterol synthesis and HMGCS1 also contributes to hepatic cholesterol synthesis. Increased activity of HMGCSR and HMGCS1 was associated with NAFLD and with fatty acid accumulation[44]. Additionally, FABP5 is a fatty acid binder normally expressed in adipocytes, but expression in hepatocytes was correlated with fatty acid infiltration in NAFLD[45]. In addition to fatty acid changes, we found downregulation of IGF-1, which leads to hyperglycemia and increases risk for diabetes seen as in NAFLD[46,47]. IGF-1 also has anti-fibrotic effects through attenuation of hepatic stellate cell (HSC) activation in murine models[48]. Furthermore, SHBG was downregulated in analysis, with decreased SHBG levels being associated with increased insulin resistance in NAFLD patients[49]. Higher levels of SHBG are also associated with lower odds for NAFLD and may have some protective effect[50]. In addition to fatty acid accumulation and glycemia, we related SREBF activity to malignant changes through upregulation of PEG10. PEG10 is a transcription factor that was found to be an oncogene in several solid cancers such as HCC, gastric cancer, and breast carcinoma[36]. PEG10 is upregulated in NASH and NAFLD and may be associated with increased risk for HCC seen in this patient population[18]. Furthermore, our results fortified other changes in NAFLD that are implicated in lipolytic changes that may induce NAFLD. CREB signaling was identified as a top canonical pathway. Awaad, *et al* showed elevated cAMP and CREB levels in a NAFLD murine model and suggest the role of cAMP and CREB as a marker of early NAFLD[51].

Accumulation of fatty acids in the liver induces chronic, low-grade inflammation, and subsequently, progression of NAFLD to NASH. Our results illustrated the inflammatory changes in NAFLD. The inflammatory response was a top disease function in our analysis (Table 3) and the pro-inflammatory cytokine TNF was a top upstream regulator. In murine models, TNF plays an essential role in NAFLD development through upregulation of inflammatory mediators and genes associated with liver fibrosis[52]. TNF also induces hepatic steatosis in murine models through upregulation of SREB proteins[53]. We also noted upregulation of several pro-inflammatory cytokines in our analysis including CXCL10 (Table 1). CXCL10 recruits T cells and macrophages and is an independent risk factor for NASH[54]. Since fatty acids lead to inflammatory changes, it is expected that SREB signaling would lead to downstream pro-inflammatory changes such as upregulation of CXCL10 (Figure 3).

Aside from inflammation and metabolic derangements, our results illustrated several other signaling and cellular processes of interest in NAFLD. One such cellular process is protein prenylation. Protein prenylation is a protein post-translational modification where farnesyl (farnesylation) or geranylgeranyl (geranylgeranylation) side chain is added to a C-terminal cysteine residue[55]. The mevalonate pathway, a top canonical pathway in our analysis, affects the ratio of farnesylation and geranylgeranylation. Alteration in this ratio is implicated in NAFLD and NAFLD-associated fibrosis[56]. In addition to post-translational protein modification, our results suggest a role for lncRNAs in NAFLD. LnRNAs are critical mediators of normal liver physiology, with aberrant expression being observed in metabolic, fibrotic, and malignant hepatic changes[17]. We found upregulation of lncRNAs in our analysis, including XIST and LINC0085. XIST is one of the earliest described lnRNAs and assists in the formation of silenced heterochromatin[57]. While not well-described in NAFLD and NASH, XIST has been shown to promote HCC and colorectal cancer[58,59]. Additionally, LINC0085 is a positive cell growth regulator in breast cancer models and may, alongside XIST, cause proliferative and pathologic changes in hepatocytes in NAFLD and NASH[16]. Lastly, recent research has connected the link between circadian rhythm genes with NAFLD[24]. Asynchronization of circadian rhythms, such as from shift work, are correlated with higher prevalence and NAFLD[60]. Per3 is a circadian rhythm gene that regulates adipogenesis, with deletion leading to increased adipogenesis in animal models[24]. Thus, downregulation of Per3 in our results may suggest dysregulation of circadian rhythm and consequent changes in regulation of adipogenesis.

NASH is a subset of NAFLD characterized by steatosis inflammation and fibrosis[61]. It typically takes years for NAFLD to progress for NASH, and while the mechanisms behind this progression are not clear, our current understanding suggests a “multi-hit hypothesis” where multiple modes of fatty acid accumulation and oxidative stress synergistically induce liver inflammation and fibrosis[61]. Aside from lifestyle modifications, obeticholic acid is the only FDA-approved treatment of NASH[62]. The growing burden of NASH necessitates new therapeutics and our analysis of NASH offers insight into potential treatment.

Ingenuity Pathway Analysis of our NASH dataset reinforces the role of cholesterol. Several of our top canonical pathways, disease network, and disease functions were related to cholesterol synthesis, lipid metabolism, adipogenesis, and metabolic disease (Figure 1, and Tables 1, 3 and 4). The role of lipids in liver injury have been described above[20,40]. Other disease functions and disease networks of note involved cell death and survival, cancer, digestive system disease, and organismal injury (Tables 3 and 4). The top upstream regulators in addition to upregulated and downregulated genes reflect activity related to these disease functions. Among our top upstream regulators were pro-inflammatory cytokines TNF and IL1B, PDGF BB, and beta-estradiol (with predicted inhibition).

As already described, inflammation is a major contributor to liver disease. It has been long shown that patients with NASH, and more so those with severe NASH, have elevated levels of TNF[63]. Elevated serum levels of TNF in NASH patients was linked to increased major adverse hepatic events[64]. While TNF inhibition reduces steatosis and fibrosis in murine models, their role in select NAFLD and NASH patient populations has still not been proven effective[52,65-67]. Similarly, IL1B signaling has pro-fibrotic and lipogenic effects in murine models and may have promise as directed therapy in NASH patients[68-70]. Lastly, the cytokine PDGF BB exerts its pro-fibrotic effects through activation of hepatic stellate cells and, consequently, is another potential drug target[71].

Experimental models have shown that estrogen has protective, anti-fibrotic activity through attenuation of HSC activation and generation of reactive oxygen species[72]. Additionally, estrogen receptor agonism in a NASH murine model had therapeutic effects through modulating bile acid receptor signaling and inhibiting fibrosis and adipogenesis[73]. Interestingly, decreased estrogen levels and other hormone changes in menopause may be related to increase risk for NAFLD and NASH[74]. Since beta-estradiol was a top upstream regulator with predicted inhibition in our NASH analysis, we applied IPA to investigate beta-estradiol signaling and its downstream genetic effects (Figure 4).

Our analysis related inhibition of beta-estradiol to derangement of several cellular processes downstream including metabolism, extracellular matrix deposition, and tumor suppression. In regard to metabolism, we related inhibition of estradiol to upregulation of IP6K3, CYP7A1, and SQLE and to downregulation of NAMP1 and IGFBP2. IP6K3 produces inositol pyrophosphates and regulates metabolic control[75]. Deletion in murine models leads to improved glucose tolerance, reduced body weight, and protection from fatty liver disease[75,76]. SQLE is involved in cholesterol synthesis and has been shown in both human and animal studies to promote development of HCC in fatty liver disease[77]. CYP7A1 is a rate-limiting enzyme in the classical pathway of bile acid synthesis with upregulated gene expression in NAFLD and NASH patients alike, but discrepancies exist in post-transcriptional protein levels[27]. The effects of fatty liver disease on CYP7A1 are inconsistent, but bile acid dysregulation is a growing hallmark in this disease[27]. NAMP1 is a critical enzyme in the synthesis of nicotinamide adenine dinucleotide (NAD+). NAD+ functions in mitochondrial oxidative phosphorylation and protection of cells from reactive oxygen species[78]. Depletion of hepatic NAD+ has been shown to be a risk factor for NAFLD in a murine model[35]. There is growing interest in targeting NAD+ in NAFLD[79]. Lastly, IGFBP2 binds to IGF1 and has a positive effects in glucose control[80]. Early epigenetic silencing, *via* methylation, of IGBFP2 predicts development of fatty liver later in mice[81].

In addition to metabolic changes, our analysis showed pro-oncogenic and fibrotic genetic changes in NASH that may relate to inhibition of beta-estradiol signaling. Through IPA, we correlated inhibition of beta-estradiol signaling to upregulation of PEG10 and FNDC5 and to downregulation of RASD1 and KLF6. Interestingly, we found upregulation of PEG10 in our NAFLD analysis and discussed its pro-oncogenic activity. RASD1 is a member of the Ras superfamily of G proteins that regulate signal transduction through G-protein coupled receptors[82]. RASD1 prevents aberrant cell growth, and its downregulation may lead to increased risk for HCC seen in fatty liver disease.[34,83] Additionally, KFL6 is a zinc finger transcriptional protein with tumor suppressor function that is inhibited in various cancers, including HCC[37]. Lastly, FNDC5 is a novel myokine that controls extracellular matrix deposition. Higher expression of FNDC5 in HSCs correlated to severity of fibrosis in NAFLD patients[29]. Our results illustrate malignant and fibrotic gene expression changes in both NAFLD and NASH stages of disease and its possible relation with inhibition of beta-estradiol signaling.

Lastly, our analysis suggests potential use of riciribine and ZSTK-474 in the treatment of NAFLD. Dysregulation of the PI3KT/AKT pathway in hepatocytes has been described in NAFLD[84]. Such dysregulation is implicated in hepatic steatosis and fibrosis. While the mechanisms underpinning pathogenesis through the PI3KT/AKT pathway are still under investigation, our results add further evidence of targeting this pathway for therapeutic benefit.

Our meta-analysis approach offers insights into NAFLD and NASH, but this approach is not without limitations. Biological samples in Gene Expression Omnibus have limitations in terms of description of samples. Some details that may present confounding variables are the co-morbidities in patients and differing stages in fatty liver disease, including degree of fibrosis. Other patient characteristics may also influence results such as medications, age, gender, and ethnicity. Samples were also taken under different conditions such as diagnosis of undifferentiated liver disease or in bariatric patients, which may lead to further differences between samples. Though there are set diagnostic criteria for hepatic steatosis on biopsy, the diagnoses were made by separate pathologists across these studies and a meta-analysis approach would not be able to account for these differences. Additionally, while transcriptomic and meta-analysis studies can offer a global view of disease function and regulatory signaling using gene expression patterns, causality necessitates more direct functional experimentation[39]. This approach itself does not offer direct experimental or clinical evidence. Nonetheless, our results offer a foundation to future studies in NAFLD and NASH that warrant further investigation with experimental and human models.

**CONCLUSION**

We utilized our platform STARGEO to produce genetic signatures from GEO datasets that provide molecular insights to fatty liver disease. We conducted to separate analysis of NAFLD and NASH liver biopsies to investigate genetic changes that define stages of fatty liver disease. Our analyses buttresses how the dysregulation in lipid homeostasis, though such regulators as the transcription factor SREBF1, contribute to steatosis. We also noted upregulation of genes implicated in oncogenesis, such as PEG10, that may partly explain the increased risk of HCC in these patients. We also describe the potential contribution on long noncoding RNAs in NAFLD pathogenesis. From our NASH analysis, we explored how beta-estradiol dysregulation may mechanistically contribute to steatosis and its several consequences such as fibrosis and oncogenesis. Lastly, we used out dataset and clue.io to identify genes that target pathologic genetic changes and signaling, such as PI3KT/AKT signaling, and found ricirbine and ZKST-474 as possible therapeutic targets. Overall, our analysis illustrates several changes that may explain progression of NAFLD pathogenesis and promising directions that warrant further investigation.

**ARTICLE HIGHLIGHTS**

***Research background***

Non-alcoholic fatty liver disease (NAFLD) pathogenesis is poorly understood but may result from a mix of exogenous and genetic factors that lead to fatty infiltration and inflammation.

***Research motivation***

NAFLD is a growing cause for liver transplant with limited therapeutic options.

***Research objectives***

To define genetic changes that underlie NAFLD and progression to non-alcoholic steatohepatitis (NASH) in pursuit of identifying promising therapeutic targets.

***Research methods***

We employed our STARGEO platform to conduct meta-analyses of publicly available liver biopsies from NAFLD and NASH patients.

***Research results***

We identified various genes implicated in inflammation and fatty infiltration, as well as signaling processes that lead to these changes. We also identified riciribine and ZSTK-474 as potential drugs.

***Research conclusions***

NAFLD and its progression to NASH is likely led by several genetic changes detailed in our manuscript. The genetic changes in our dataset are targeted by ricirbine and ZSTK-474 and warrants further study.

***Research perspectives***

As NAFLD becomes an increasing clinical burden, a bioinformatics approach is valuable in understanding causes and elucidating treatment avenues.

**REFERENCES**

1 **Levene AP**, Goldin RD. The epidemiology, pathogenesis and histopathology of fatty liver disease. *Histopathology* 2012; **61**: 141-152 [PMID: 22372457 DOI: 10.1111/j.1365-2559.2011.04145.x]

2 **Williams CD**, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL, Harrison SA. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. *Gastroenterology* 2011; **140**: 124-131 [PMID: 20858492 DOI: 10.1053/j.gastro.2010.09.038]

3 **Adams LA**, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. *Gastroenterology* 2005; **129**: 113-121 [PMID: 16012941 DOI: 10.1053/j.gastro.2005.04.014]

4 **Clark JM**, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. *Am J Gastroenterol* 2003; **98**: 960-967 [PMID: 12809815 DOI: 10.1111/j.1572-0241.2003.07486.x]

5 **Holmberg SD**, Spradling PR, Moorman AC, Denniston MM. Hepatitis C in the United States. *N Engl J Med* 2013; **368**: 1859-1861 [PMID: 23675657 DOI: 10.1056/NEJMp1302973]

6 **Tilg H**, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. *Hepatology* 2010; **52**: 1836-1846 [PMID: 21038418 DOI: 10.1002/hep.24001]

7 **Hadley D**, Pan J, El-Sayed O, Aljabban J, Aljabban I, Azad TD, Hadied MO, Raza S, Rayikanti BA, Chen B, Paik H, Aran D, Spatz J, Himmelstein D, Panahiazar M, Bhattacharya S, Sirota M, Musen MA, Butte AJ. Precision annotation of digital samples in NCBI's gene expression omnibus. *Sci Data* 2017; **4**: 170125 [PMID: 28925997 DOI: 10.1038/sdata.2017.125]

8 **DerSimonian R**, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986; **7**: 177-188 [PMID: 3802833 DOI: 10.1016/0197-2456(86)90046-2]

9 **Ahrens M**, Ammerpohl O, von Schönfels W, Kolarova J, Bens S, Itzel T, Teufel A, Herrmann A, Brosch M, Hinrichsen H, Erhart W, Egberts J, Sipos B, Schreiber S, Häsler R, Stickel F, Becker T, Krawczak M, Röcken C, Siebert R, Schafmayer C, Hampe J. DNA methylation analysis in nonalcoholic fatty liver disease suggests distinct disease-specific and remodeling signatures after bariatric surgery. *Cell Metab* 2013; **18**: 296-302 [PMID: 23931760 DOI: 10.1016/j.cmet.2013.07.004]

10 **Frades I**, Andreasson E, Mato JM, Alexandersson E, Matthiesen R, Martínez-Chantar ML. Integrative genomic signatures of hepatocellular carcinoma derived from nonalcoholic Fatty liver disease. *PLoS One* 2015; **10**: e0124544 [PMID: 25993042 DOI: 10.1371/journal.pone.0124544]

11 **Xanthakos SA**, Jenkins TM, Kleiner DE, Boyce TW, Mourya R, Karns R, Brandt ML, Harmon CM, Helmrath MA, Michalsky MP, Courcoulas AP, Zeller MH, Inge TH; Teen-LABS Consortium. High Prevalence of Nonalcoholic Fatty Liver Disease in Adolescents Undergoing Bariatric Surgery. *Gastroenterology* 2015; **149**: 623-34.e8 [PMID: 26026390 DOI: 10.1053/j.gastro.2015.05.039]

12 **Guo J**, Fang W, Sun L, Lu Y, Dou L, Huang X, Tang W, Yu L, Li J. Ultraconserved element uc.372 drives hepatic lipid accumulation by suppressing miR-195/miR4668 maturation. *Nat Commun* 2018; **9**: 612 [PMID: 29426937 DOI: 10.1038/s41467-018-03072-8]

13 **Kleiner DE**, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. *Hepatology* 2005; **41**: 1313-1321 [PMID: 15915461 DOI: 10.1002/hep.20701]

14 **Krämer A**, Green J, Pollard J Jr, Tugendreich S. Causal analysis approaches in Ingenuity Pathway Analysis. *Bioinformatics* 2014; **30**: 523-530 [PMID: 24336805 DOI: 10.1093/bioinformatics/btt703]

15 **Subramanian A**, Narayan R, Corsello SM, Peck DD, Natoli TE, Lu X, Gould J, Davis JF, Tubelli AA, Asiedu JK, Lahr DL, Hirschman JE, Liu Z, Donahue M, Julian B, Khan M, Wadden D, Smith IC, Lam D, Liberzon A, Toder C, Bagul M, Orzechowski M, Enache OM, Piccioni F, Johnson SA, Lyons NJ, Berger AH, Shamji AF, Brooks AN, Vrcic A, Flynn C, Rosains J, Takeda DY, Hu R, Davison D, Lamb J, Ardlie K, Hogstrom L, Greenside P, Gray NS, Clemons PA, Silver S, Wu X, Zhao WN, Read-Button W, Wu X, Haggarty SJ, Ronco LV, Boehm JS, Schreiber SL, Doench JG, Bittker JA, Root DE, Wong B, Golub TR. A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles. *Cell* 2017; **171**: 1437-1452.e17 [PMID: 29195078 DOI: 10.1016/j.cell.2017.10.049]

16 **Abba MC**, Canzoneri R, Gurruchaga A, Lee J, Tatineni P, Kil H, Lacunza E, Aldaz CM. *LINC00885* a Novel Oncogenic Long Non-Coding RNA Associated with Early Stage Breast Cancer Progression. *Int J Mol Sci* 2020; **21** [PMID: 33049922 DOI: 10.3390/ijms21197407]

17 **Mahpour A**, Mullen AC. Our emerging understanding of the roles of long non-coding RNAs in normal liver function, disease, and malignancy. *JHEP Rep* 2021; **3**: 100177 [PMID: 33294829 DOI: 10.1016/j.jhepr.2020.100177]

18 **Arendt BM**, Comelli EM, Ma DW, Lou W, Teterina A, Kim T, Fung SK, Wong DK, McGilvray I, Fischer SE, Allard JP. Altered hepatic gene expression in nonalcoholic fatty liver disease is associated with lower hepatic n-3 and n-6 polyunsaturated fatty acids. *Hepatology* 2015; **61**: 1565-1578 [PMID: 25581263 DOI: 10.1002/hep.27695]

19 **Keravis T**, Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments. *Br J Pharmacol* 2012; **165**: 1288-1305 [PMID: 22014080 DOI: 10.1111/j.1476-5381.2011.01729.x]

20 **Carr RM**, Ahima RS. Pathophysiology of lipid droplet proteins in liver diseases. *Exp Cell Res* 2016; **340**: 187-192 [PMID: 26515554 DOI: 10.1016/j.yexcr.2015.10.021]

21 **Sun C**, Fan JG, Qiao L. Potential epigenetic mechanism in non-alcoholic Fatty liver disease. *Int J Mol Sci* 2015; **16**: 5161-5179 [PMID: 25751727 DOI: 10.3390/ijms16035161]

22 **Buqué X**, Martínez MJ, Cano A, Miquilena-Colina ME, García-Monzón C, Aspichueta P, Ochoa B. A subset of dysregulated metabolic and survival genes is associated with severity of hepatic steatosis in obese Zucker rats. *J Lipid Res* 2010; **51**: 500-513 [PMID: 19783528 DOI: 10.1194/jlr.m001966]

23 **Nasiri M**, Nikolaou N, Parajes S, Krone NP, Valsamakis G, Mastorakos G, Hughes B, Taylor A, Bujalska IJ, Gathercole LL, Tomlinson JW. 5α-Reductase Type 2 Regulates Glucocorticoid Action and Metabolic Phenotype in Human Hepatocytes. *Endocrinology* 2015; **156**: 2863-2871 [PMID: 25974403 DOI: 10.1210/en.2015-1149]

24 **Shi D**, Chen J, Wang J, Yao J, Huang Y, Zhang G, Bao Z. Circadian Clock Genes in the Metabolism of Non-alcoholic Fatty Liver Disease. *Front Physiol* 2019; **10**: 423 [PMID: 31139087 DOI: 10.3389/fphys.2019.00423]

25 **Wang S**, Hu M, Qian Y, Jiang Z, Shen L, Fu L, Hu Y. CHI3L1 in the pathophysiology and diagnosis of liver diseases. *Biomed Pharmacother* 2020; **131**: 110680 [PMID: 32861071 DOI: 10.1016/j.biopha.2020.110680]

26 **Chiang JY**. Bile acids: regulation of synthesis. *J Lipid Res* 2009; **50**: 1955-1966 [PMID: 19346330 DOI: 10.1194/jlr.r900010-jlr200]

27 **Zhang X,** Deng R. Dysregulation of Bile Acids in Patients with NAFLD. In Nonalcoholic Fatty Liver Disease - An Update, 2019 [DOI: 10.5772/intechopen.81474]

28 **Paul HS**, Sekas G, Adibi SA. Carnitine biosynthesis in hepatic peroxisomes. Demonstration of gamma-butyrobetaine hydroxylase activity. *Eur J Biochem* 1992; **203**: 599-605 [PMID: 1735445 DOI: 10.1111/j.1432-1033.1992.tb16589.x]

29 **Gao F**, Zheng KI, Zhu PW, Li YY, Ma HL, Li G, Tang LJ, Rios RS, Liu WY, Pan XY, Targher G, Byrne CD, Chen YP, Zheng MH. *FNDC5* polymorphism influences the association between sarcopenia and liver fibrosis in adults with biopsy-proven non-alcoholic fatty liver disease. *Br J Nutr* 2021; **126**: 813-824 [PMID: 33198849 DOI: 10.1017/s0007114520004559]

30 **Brady GF**, Kwan R, Bragazzi Cunha J, Elenbaas JS, Omary MB. Lamins and Lamin-Associated Proteins in Gastrointestinal Health and Disease. *Gastroenterology* 2018; **154**: 1602-1619.e1 [PMID: 29549040 DOI: 10.1053/j.gastro.2018.03.026]

31 **Shibuya A**, Honda S. Immune regulation by Fcα/μ receptor (CD351) on marginal zone B cells and follicular dendritic cells. *Immunol Rev* 2015; **268**: 288-295 [PMID: 26497528 DOI: 10.1111/imr.12345]

32 **Borkham-Kamphorst E**, Schaffrath C, Van de Leur E, Haas U, Tihaa L, Meurer SK, Nevzorova YA, Liedtke C, Weiskirchen R. The anti-fibrotic effects of CCN1/CYR61 in primary portal myofibroblasts are mediated through induction of reactive oxygen species resulting in cellular senescence, apoptosis and attenuated TGF-β signaling. *Biochim Biophys Acta* 2014; **1843**: 902-914 [PMID: 24487063 DOI: 10.1016/j.bbamcr.2014.01.023]

33 **Preston GA**, Lyon TT, Yin Y, Lang JE, Solomon G, Annab L, Srinivasan DG, Alcorta DA, Barrett JC. Induction of apoptosis by c-Fos protein. *Mol Cell Biol* 1996; **16**: 211-218 [PMID: 8524298 DOI: 10.1128/mcb.16.1.211]

34 **Vaidyanathan G**, Cismowski MJ, Wang G, Vincent TS, Brown KD, Lanier SM. The Ras-related protein AGS1/RASD1 suppresses cell growth. *Oncogene* 2004; **23**: 5858-5863 [PMID: 15184869 DOI: 10.1038/sj.onc.1207774]

35 **Zhou CC**, Yang X, Hua X, Liu J, Fan MB, Li GQ, Song J, Xu TY, Li ZY, Guan YF, Wang P, Miao CY. Hepatic NAD(+) deficiency as a therapeutic target for non-alcoholic fatty liver disease in ageing. *Br J Pharmacol* 2016; **173**: 2352-2368 [PMID: 27174364 DOI: 10.1111/bph.13513]

36 **Xie T**, Pan S, Zheng H, Luo Z, Tembo KM, Jamal M, Yu Z, Yu Y, Xia J, Yin Q, Wang M, Yuan W, Zhang Q, Xiong J. PEG10 as an oncogene: expression regulatory mechanisms and role in tumor progression. *Cancer Cell Int* 2018; **18**: 112 [PMID: 30123090 DOI: 10.1186/s12935-018-0610-3]

37 **Kremer-Tal S**, Reeves HL, Narla G, Thung SN, Schwartz M, Difeo A, Katz A, Bruix J, Bioulac-Sage P, Martignetti JA, Friedman SL. Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. *Hepatology* 2004; **40**: 1047-1052 [PMID: 15486921 DOI: 10.1002/hep.20460]

38 **Younossi ZM**, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology* 2016; **64**: 73-84 [PMID: 26707365 DOI: 10.1002/hep.28431]

39 **Russo G**, Zegar C, Giordano A. Advantages and limitations of microarray technology in human cancer. *Oncogene* 2003; **22**: 6497-6507 [PMID: 14528274 DOI: 10.1038/sj.onc.1206865]

40 **Berlanga A**, Guiu-Jurado E, Porras JA, Auguet T. Molecular pathways in non-alcoholic fatty liver disease. *Clin Exp Gastroenterol* 2014; **7**: 221-239 [PMID: 25045276 DOI: 10.2147/ceg.s62831]

41 **Kerr TA**, Davidson NO. Cholesterol and nonalcoholic fatty liver disease: renewed focus on an old villain. *Hepatology* 2012; **56**: 1995-1998 [PMID: 23115010 DOI: 10.1002/hep.26088]

42 **Moslehi A**, Hamidi-Zad Z. Role of SREBPs in Liver Diseases: A Mini-review. *J Clin Transl Hepatol* 2018; **6**: 332-338 [PMID: 30271747 DOI: 10.14218/jcth.2017.00061]

43 **Qiao A**, Liang J, Ke Y, Li C, Cui Y, Shen L, Zhang H, Cui A, Liu X, Liu C, Chen Y, Zhu Y, Guan Y, Fang F, Chang Y. Mouse patatin-like phospholipase domain-containing 3 influences systemic lipid and glucose homeostasis. *Hepatology* 2011; **54**: 509-521 [PMID: 21547936 DOI: 10.1002/hep.24402]

44 **Arguello G**, Balboa E, Arrese M, Zanlungo S. Recent insights on the role of cholesterol in non-alcoholic fatty liver disease. *Biochim Biophys Acta* 2015; **1852**: 1765-1778 [PMID: 26027904 DOI: 10.1016/j.bbadis.2015.05.015]

45 **Westerbacka J**, Kolak M, Kiviluoto T, Arkkila P, Sirén J, Hamsten A, Fisher RM, Yki-Järvinen H. Genes involved in fatty acid partitioning and binding, lipolysis, monocyte/macrophage recruitment, and inflammation are overexpressed in the human fatty liver of insulin-resistant subjects. *Diabetes* 2007; **56**: 2759-2765 [PMID: 17704301 DOI: 10.2337/db07-0156]

46 **Stanley TL**, Fourman LT, Zheng I, McClure CM, Feldpausch MN, Torriani M, Corey KE, Chung RT, Lee H, Kleiner DE, Hadigan CM, Grinspoon SK. Relationship of IGF-1 and IGF-Binding Proteins to Disease Severity and Glycemia in Nonalcoholic Fatty Liver Disease. *J Clin Endocrinol Metab* 2021; **106**: e520-e533 [PMID: 33125080 DOI: 10.1210/clinem/dgaa792]

47 **Yao Y**, Miao X, Zhu D, Li D, Zhang Y, Song C, Liu K. Insulin-like growth factor-1 and non-alcoholic fatty liver disease: a systemic review and meta-analysis. *Endocrine* 2019; **65**: 227-237 [PMID: 31243652 DOI: 10.1007/s12020-019-01982-1]

48 **Nishizawa H**, Iguchi G, Fukuoka H, Takahashi M, Suda K, Bando H, Matsumoto R, Yoshida K, Odake Y, Ogawa W, Takahashi Y. IGF-I induces senescence of hepatic stellate cells and limits fibrosis in a p53-dependent manner. *Sci Rep* 2016; **6**: 34605 [PMID: 27721459 DOI: 10.1038/srep34605]

49 **Ye J**, Yao Z, Tan A, Gao Y, Chen Y, Lin X, He R, Tang R, Hu Y, Zhang H, Yang X, Wang Q, Jiang Y, Mo Z. Low Serum Sex Hormone-Binding Globulin Associated with Insulin Resistance in Men with Nonalcoholic Fatty Liver Disease. *Horm Metab Res* 2017; **49**: 359-364 [PMID: 28282659 DOI: 10.1055/s-0043-102690]

50 **Jaruvongvanich V**, Sanguankeo A, Riangwiwat T, Upala S. Testosterone, Sex Hormone-Binding Globulin and Nonalcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis. *Ann Hepatol* 2017; **16**: 382-394 [PMID: 28425408 DOI: 10.5604/01.3001.0009.8593]

51 **Awaad AK,** Kamel MA, Mohamed MM. The role of hepatic transcription factor cAMP response element-binding protein (CREB) during the development of experimental nonalcoholic fatty liver: a biochemical and histomorphometric study. *Egypt Liver J* 2020 [DOI: 10.1186/s43066-020-00046-8]

52 **Kakino S**, Ohki T, Nakayama H, Yuan X, Otabe S, Hashinaga T, Wada N, Kurita Y, Tanaka K, Hara K, Soejima E, Tajiri Y, Yamada K. Pivotal Role of TNF-α in the Development and Progression of Nonalcoholic Fatty Liver Disease in a Murine Model. *Horm Metab Res* 2018; **50**: 80-87 [PMID: 28922680 DOI: 10.1055/s-0043-118666]

53 **Endo M**, Masaki T, Seike M, Yoshimatsu H. TNF-alpha induces hepatic steatosis in mice by enhancing gene expression of sterol regulatory element binding protein-1c (SREBP-1c). *Exp Biol Med (Maywood)* 2007; **232**: 614-621 [PMID: 17463157 DOI: 10.1038/oby.2001.95]

54 **Xu Z**, Zhang X, Lau J, Yu J. C-X-C motif chemokine 10 in non-alcoholic steatohepatitis: role as a pro-inflammatory factor and clinical implication. *Expert Rev Mol Med* 2016; **18**: e16 [PMID: 27669973 DOI: 10.1017/erm.2016.16]

55 **Zhang FL**, Casey PJ. Protein prenylation: molecular mechanisms and functional consequences. *Annu Rev Biochem* 1996; **65**: 241-269 [PMID: 8811180 DOI: 10.1146/annurev.bi.65.070196.001325]

56 **Zhao Y**, Wu TY, Zhao MF, Li CJ. The balance of protein farnesylation and geranylgeranylation during the progression of nonalcoholic fatty liver disease. *J Biol Chem* 2020; **295**: 5152-5162 [PMID: 32139507 DOI: 10.1074/jbc.rev119.008897]

57 **Wutz A**, Rasmussen TP, Jaenisch R. Chromosomal silencing and localization are mediated by different domains of Xist RNA. *Nat Genet* 2002; **30**: 167-174 [PMID: 11780141 DOI: 10.1038/ng820]

58 **Chang S**, Chen B, Wang X, Wu K, Sun Y. Long non-coding RNA XIST regulates PTEN expression by sponging miR-181a and promotes hepatocellular carcinoma progression. *BMC Cancer* 2017; **17**: 248 [PMID: 28388883 DOI: 10.1186/s12885-017-3216-6]

59 **Chen DL**, Chen LZ, Lu YX, Zhang DS, Zeng ZL, Pan ZZ, Huang P, Wang FH, Li YH, Ju HQ, Xu RH. Long noncoding RNA XIST expedites metastasis and modulates epithelial-mesenchymal transition in colorectal cancer. *Cell Death Dis* 2017; **8**: e3011 [PMID: 28837144 DOI: 10.1038/cddis.2017.421]

60 **Johnston JD**. Physiological links between circadian rhythms, metabolism and nutrition. *Exp Physiol* 2014; **99**: 1133-1137 [PMID: 25210113 DOI: 10.1113/expphysiol.2014.078295]

61 **Peng C**, Stewart AG, Woodman OL, Ritchie RH, Qin CX. Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments. *Front Pharmacol* 2020; **11**: 603926 [PMID: 33343375 DOI: 10.3389/fphar.2020.603926]

62 **Younossi ZM**, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, Bedossa P, Geier A, Beckebaum S, Newsome PN, Sheridan D, Sheikh MY, Trotter J, Knapple W, Lawitz E, Abdelmalek MF, Kowdley KV, Montano-Loza AJ, Boursier J, Mathurin P, Bugianesi E, Mazzella G, Olveira A, Cortez-Pinto H, Graupera I, Orr D, Gluud LL, Dufour JF, Shapiro D, Campagna J, Zaru L, MacConell L, Shringarpure R, Harrison S, Sanyal AJ; REGENERATE Study Investigators. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. *Lancet* 2019; **394**: 2184-2196 [PMID: 31813633 DOI: 10.3410/f.725273573.793504763]

63 **Crespo J**, Cayón A, Fernández-Gil P, Hernández-Guerra M, Mayorga M, Domínguez-Díez A, Fernández-Escalante JC, Pons-Romero F. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. *Hepatology* 2001; **34**: 1158-1163 [PMID: 11732005 DOI: 10.1053/jhep.2001.29628]

64 **Zhu Z,** Li S. Association between tumor necrosis factor-α and the risk of hepatic events: A median 3 years follow-up study. *Hepat Mon* 2018 [DOI: 10.5812/hepatmon.65537]

65 **Park C**, Balaji N, Jung S, Choi J, Ju M, Lee S, Kim J, Bong S, Chung S, Lee YJ, Yi J. Advanced Passivation Technology and Loss Factor Minimization for High Efficiency Solar Cells. *J Nanosci Nanotechnol* 2015; **15**: 7699-7705 [PMID: 26726397 DOI: 10.1007/s40139-015-0093-z]

66 **Tang KT**, Dufour JF, Chen PH, Hernaez R, Hutfless S. Antitumour necrosis factor-α agents and development of new-onset cirrhosis or non-alcoholic fatty liver disease: a retrospective cohort. *BMJ Open Gastroenterol* 2020; **7**: e000349 [PMID: 32377366 DOI: 10.1136/bmjgast-2019-000349]

67 **Wandrer F**, Liebig S, Marhenke S, Vogel A, John K, Manns MP, Teufel A, Itzel T, Longerich T, Maier O, Fischer R, Kontermann RE, Pfizenmaier K, Schulze-Osthoff K, Bantel H. TNF-Receptor-1 inhibition reduces liver steatosis, hepatocellular injury and fibrosis in NAFLD mice. *Cell Death Dis* 2020; **11**: 212 [PMID: 32235829 DOI: 10.1038/s41419-020-2411-6]

68 **Dobre M**, Milanesi E, Mănuc TE, Arsene DE, Ţieranu CG, Maj C, Becheanu G, Mănuc M. Differential Intestinal Mucosa Transcriptomic Biomarkers for Crohn's Disease and Ulcerative Colitis. *J Immunol Res* 2018; **2018**: 9208274 [PMID: 30417021 DOI: 10.1155/2018/9208274]

69 **Negrin KA**, Roth Flach RJ, DiStefano MT, Matevossian A, Friedline RH, Jung D, Kim JK, Czech MP. IL-1 signaling in obesity-induced hepatic lipogenesis and steatosis. *PLoS One* 2014; **9**: e107265 [PMID: 25216251 DOI: 10.1371/journal.pone.0107265]

70 **Tilg H**, Effenberger M, Adolph TE. A role for IL-1 inhibitors in the treatment of non-alcoholic fatty liver disease (NAFLD)? *Expert Opin Investig Drugs* 2020; **29**: 103-106 [PMID: 31615278 DOI: 10.1080/13543784.2020.1681397]

71 **Ying HZ**, Chen Q, Zhang WY, Zhang HH, Ma Y, Zhang SZ, Fang J, Yu CH. PDGF signaling pathway in hepatic fibrosis pathogenesis and therapeutics (Review). *Mol Med Rep* 2017; **16**: 7879-7889 [PMID: 28983598 DOI: 10.3892/mmr.2017.7641]

72 **Itagaki T**, Shimizu I, Cheng X, Yuan Y, Oshio A, Tamaki K, Fukuno H, Honda H, Okamura Y, Ito S. Opposing effects of oestradiol and progesterone on intracellular pathways and activation processes in the oxidative stress induced activation of cultured rat hepatic stellate cells. *Gut* 2005; **54**: 1782-1789 [PMID: 16284289 DOI: 10.1136/gut.2004.053728]

73 **Ponnusamy S**, Tran QT, Thiyagarajan T, Miller DD, Bridges D, Narayanan R. An estrogen receptor β-selective agonist inhibits non-alcoholic steatohepatitis in preclinical models by regulating bile acid and xenobiotic receptors. *Exp Biol Med (Maywood)* 2017; **242**: 606-616 [PMID: 28092182 DOI: 10.1177/1535370216688569]

74 **Venetsanaki V**, Polyzos SA. Menopause and Non-Alcoholic Fatty Liver Disease: A Review Focusing on Therapeutic Perspectives. *Curr Vasc Pharmacol* 2019; **17**: 546-555 [PMID: 29992886 DOI: 10.2174/1570161116666180711121949]

75 **Moritoh Y**, Oka M, Yasuhara Y, Hozumi H, Iwachidow K, Fuse H, Tozawa R. Inositol Hexakisphosphate Kinase 3 Regulates Metabolism and Lifespan in Mice. *Sci Rep* 2016; **6**: 32072 [PMID: 27577108 DOI: 10.1038/srep32072]

76 **Mukherjee S**, Haubner J, Chakraborty A. Targeting the Inositol Pyrophosphate Biosynthetic Enzymes in Metabolic Diseases. *Molecules* 2020; **25** [PMID: 32204420 DOI: 10.3390/molecules25061403]

77 **Liu D**, Wong CC, Fu L, Chen H, Zhao L, Li C, Zhou Y, Zhang Y, Xu W, Yang Y, Wu B, Cheng G, Lai PB, Wong N, Sung JJY, Yu J. Squalene epoxidase drives NAFLD-induced hepatocellular carcinoma and is a pharmaceutical target. *Sci Transl Med* 2018; **10** [PMID: 29669855 DOI: 10.1126/scitranslmed.aap9840]

78 **Valko M**, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. *Int J Biochem Cell Biol* 2007; **39**: 44-84 [PMID: 16978905 DOI: 10.1016/j.biocel.2006.07.001]

79 **Guarino M**, Dufour JF. Nicotinamide and NAFLD: Is There Nothing New Under the Sun? *Metabolites* 2019; **9** [PMID: 31510030 DOI: 10.3390/metabo9090180]

80 **Hedbacker K**, Birsoy K, Wysocki RW, Asilmaz E, Ahima RS, Farooqi IS, Friedman JM. Antidiabetic effects of IGFBP2, a leptin-regulated gene. *Cell Metab* 2010; **11**: 11-22 [PMID: 20074524 DOI: 10.1016/j.cmet.2009.11.007]

81 **Kammel A**, Saussenthaler S, Jähnert M, Jonas W, Stirm L, Hoeflich A, Staiger H, Fritsche A, Häring HU, Joost HG, Schürmann A, Schwenk RW. Early hypermethylation of hepatic Igfbp2 results in its reduced expression preceding fatty liver in mice. *Hum Mol Genet* 2016; **25**: 2588-2599 [PMID: 27126637 DOI: 10.1093/hmg/ddw121]

82 **Greenwood MP**, Greenwood M, Mecawi AS, Antunes-Rodrigues J, Paton JF, Murphy D. Rasd1, a small G protein with a big role in the hypothalamic response to neuronal activation. *Mol Brain* 2016; **9**: 1 [PMID: 26739966 DOI: 10.1186/s13041-015-0182-2]

83 **Pennisi G**, Celsa C, Giammanco A, Spatola F, Petta S. The Burden of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: Screening Issue and Future Perspectives. *Int J Mol Sci* 2019; **20** [PMID: 31717576 DOI: 10.3390/ijms20225613]

84 **Matsuda S**, Kobayashi M, Kitagishi Y. Roles for PI3K/AKT/PTEN Pathway in Cell Signaling of Nonalcoholic Fatty Liver Disease. *ISRN Endocrinol* 2013; **2013**: 472432 [PMID: 23431468 DOI: 10.1155/2013/472432]

**Footnotes**

**Institutional review board statement:** Data was publicly available so IRB approval was not needed.

**Conflict-of-interest statement:** None of the authors have any conflict of interest.

**Data sharing statement:** Data was taken by already available public pathologic samples.

**CONSORT 2010 statement:** The authors have read the CONSORT 2010 statement, and the manuscript was prepared and revised according to the CONSORT 2010 statement.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Corresponding Author's Membership in Professional Societies:** American Association for the Study of Liver Diseases; American Gastroenterological Association.

**Peer-review started:** March 2, 2022

**First decision:** April 13, 2022

**Article in press:** June 14, 2022

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): 0


Grade C (Good): C

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Du Y, China; Kotlyarov S, Russia **A-Editor:** Lin FY **S-Editor:** Wang LL **L-Editor:** A **P-Editor:** Cai YX


**Figure Legends**




**Figure 1 We used Ingenuity Pathway Analysis, gene function feature to define pathologic processes in our non-alcoholic steatohepatitis analysis.** This Figure highlights the adipogenic changes in hepatocytes from non-alcoholic steatohepatitis patients. Prediction legend illustrates relations of molecules and Figure generated using Ingenuity Pathway Analysis.




**Figure 2 Top network (Lipid metabolism, small molecule biochemistry, vitamin and mineral metabolism) identified by Ingenuity Pathway Analysis Network analysis of non-alcoholic fatty liver disease.** Legend illustrates class of the gene. Red indicates upregulation and green downregulation, with shade depicting magnitude of change. Solid and dashed lines depict direct and indirect, respectively, relationship between genes. Figure generated using Ingenuity Pathway Analysis.



**Figure 3 Ingenuity Pathway Analysis of SREBF1 signaling in non-alcoholic fatty liver disease.** Genes are implicated in several potential disease processes including the inflammation, metabolism, and transport. Legend illustrates relationship between genes. See Figure 2 legend for identification of shapes. Figure generated using Ingenuity Pathway Analysis.



**Figure 4 Ingenuity Pathway Analysis of beta-estradiol signaling in non-alcoholic steatohepatitis.** Genes are implicated in several potential disease processes including the metabolism, cancer development, bile acid synthesis, and cell survival. Legend illustrates relationship between genes. See Figure 2 legend for identification of shapes. Figure generated using Ingenuity Pathway Analysis.



**Figure 5 Pathologic gene patterns shared in the non-alcoholic fatty liver disease and non-alcoholic steatohepatitis meta-analyeses are highlighted above.** This dataset was inputted in clue.io to identify potential drug targets. We found riciribine (an AKT inhibitor) and ZSTK-474 (a PI3K inhibitor) as drugs that best targeted the gene expression above.

**Table 1 Top canonical pathways for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis identified by Ingenuity Pathway Analysis**

|  |  |  |
| --- | --- | --- |
|  | **Overlap** | ***P* value** |
| Top canonical pathways in NAFLD *vs* healthy control | | |
| Liver X receptor / retinoid X receptor activation | 5/121 | 4.35E-05 |
| Superpathway of cholesterol biosynthesis | 3/29 | 1.08E-04 |
| Granulocyte adhesion and diapedesis | 5/173 | 2.34E-04 |
| CREB signaling | 8/596 | 6.25E-04 |
| Mevalonate pathway I | 2/14 | 8.96E-04 |
| Top canonical pathways in NASH *vs* healthy control | | |
| Cholesterol biosynthesis I | 4/13 | 5.48E-05 |
| Cholesterol Biosynthesis II (*via* 24,25-dihydrolanosterol) | 4/13 | 5.48E-05 |
| Cholesterol biosynthesis III (*via* desmosterol) | 4/13 | 5.48E-05 |
| IGF-1 signaling | 9/106 | 9.16E-05 |
| Superpathway of cholesterol biosynthesis | 5/28 | 1.05E-04 |

NAFLD: Non-alcoholic fatty liver disease; CREB: cAMP response element binding protein.

**Table 2 Summary of the list genes that are the most upregulated and downregulated in our meta-analysis of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis liver samples compared to healthy controls**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Top upregulated genes** | | | | **Top downregulated genes** | | | |
| NAFLD *vs* Healthy | | NASH *vs* Healthy | | NAFLD *vs* Healthy | | NASH *vs* Healthy | |
| XIST | 0.326 | Crystallin alpha A | 1.185 | LINC02535 | -0.198 | MT1L | -0.454 |
| PEG10 | 0.267 | CYP7A1 | 0.409 | GPR88 | -0.194 | CYR61 | -0.386 |
| SUCO | 0.252 | BBOX1 | 0.381 | CYP1A1 | -0.170 | FOSB | -0.339 |
| CBWD5 | 0.239 | TAF4B | 0.355 | IGFBP2 | -0.168 | IGFBP2 | -0.326 |
| TMEM154 | 0.228 | FNDC5 | 0.346 | P4HA1 | -0.166 | FOS | -0.275 |
| HMGCR | 0.225 | MROH2A | 0.293 | TSPAN13 | -0.159 | CAPZA3 | -0.254 |
| LINC00885 | 0.216 | Fc alpha and mu receptor | 0.265 | NR4A2 | -0.148 | CSRNP1 | -0.254 |
| Chitinase 3 Like 1 | 0.186 | IL13RA2 | 0.252 | PER3 | -0.145 | PCDHB19P | -0.252 |
| MEP1B | 0.181 | ABHD1 | 0.250 | SHBG | -0.135 | Nicotinamide phosphoribosyltransferase | -0.240 |
| Phosphodiesterase 11A | 0.180 | Muscular LMNA interacting protein | 0.229 | CENPO | -0.131 | RASD1 | -0.237 |

NAFLD: Non-alcoholic fatty liver disease; NASH: Non-alcoholic steatohepatitis.

**Table 3 Top disease functions for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis identified by Ingenuity Pathway Analysis**

|  |  |
| --- | --- |
| **Top disease functions in NAFLD *vs* healthy control** | ***P* values** |
| Inflammatory response | 1.67E-03 |
| Liver lesion | 6.59E-05 |
| Cell movement of epithelial cells | 3.88E-04 |
| Activation of cells | 5.30E-04 |
| Synthesis of lipid | 5.49E-08 |
| Accumulation of lipid | 6.12E-04 |
| Concentration of lipid | 2.38E-06 |
| Fibrosis | 3.75E-05 |
| Secretion of lipid | 1.06E-03 |
| Hepatic injury | 1.54E-04 |
| Organismal injury and abnormalities | 5.10E-16 |
| Cancer | 3.47E-15 |
| Dermatologic diseases and conditions | 5.20E-11 |
| Metabolic disease | 6.69E-10 |
| Lipid metabolism | 8.09E-12 |
| Molecular transport | 7.06E-12 |
| Small molecule biochemistry | 9.86E-11 |
| Cell death and survival | 5.05E-8 |
| Cellular movement | 6.28E-8 |
| Adipogenesis | 1.31E-7 |

NAFLD: Non-alcoholic fatty liver disease.

**Table 4 Top five molecular networks associated with genetic differences in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis liver biopsies compared to healthy controls. Disease networks were identified using Ingenuity Pathway Analysis**

|  |  |
| --- | --- |
| **Top molecular networks in NAFLD *vs* healthy control** | |
| Lipid metabolism, small molecule biochemistry, vitamin and mineral metabolism | 34 |
| Cell-to-cell signaling and interaction, cellular movement, hematological system development and function | 23 |
| Connective tissue disorders, inflammatory disease, organismal injury and abnormalities | 19 |
| Cellular development, connective tissue development and function, skeletal and muscular system development and function | 16 |
| Cell death and survival, neurological disease, organismal injury and abnormalities | 16 |
| Amino acid metabolism, molecular transport, small molecule biochemistry | 34 |
| Cellular development, skeletal and muscular system development and function, tissue development | 34 |
| Hereditary disorder, neurological disease, organismal injury and abnormalities | 32 |
| Digestive system development and function, lipid metabolism, small molecule biochemistry | 29 |
| Cell cycle, cell death and survival, cellular movement | 29 |

NAFLD: Non-alcoholic fatty liver disease.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**